Delivery Order SPE2DB22D2206-SPE2DB25FDQ65

Award Date 10/4/24
Potential Completion Date 10/7/24
Potential Value $22K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of RINVOQ ER 30 MG TABLET UU 30S, a prescription medication. The contract has a ceiling value of $33,890.35 and an ultimate completion date of September 19, 2024. It is a firm fixed-price contract and does not have a set-aside designation. As a key supplier to various federal healthcare programs, including those...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RINVOQ ER 30 MG TABLET UU 30S, a pharmaceutical product. The contract has a ceiling value of $32,794.15 and a completion date of June 13, 2025. It is a firm fixed-price contract and is not set aside for any specific business type. AmerisourceBergen holds a significant...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RINVOQ ER 30 MG TABLET, a pharmaceutical product. The contract has a ceiling value of $18,842.90 and a completion date of June 5, 2025. It is a Firm Fixed Price contract, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant...
This is a Delivery Order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the supply of RINVOQ ER 15 MG TABLET, a medication, with a ceiling value of $11,886.85 and a completion date of June 13, 2025. The contract is a Firm Fixed Price arrangement without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RINVOQ ER 30 MG TABLET, a pharmaceutical product. The contract has a ceiling value of $10,780.17 and a completion date of May 1, 2025. It is a firm fixed-price contract, and there is no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RINVOQ ER 15 MG TABLET, a pharmaceutical product, with a ceiling value of $5,041.29 and a completion date of December 28, 2022. The contract is a firm-fixed-price, non-set-aside contract. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the...
This is a delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is for the delivery of RINVOQ ER 30 MG TABLET UU 30S, a pharmaceutical product, with a ceiling value of $14,793.76 and a completion date of June 13, 2025. The contract is a firm fixed-price, non-set-aside award, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RINVOQ ER 15 MG tablets. The contract has a ceiling value of $21,219.50 and a completion date of February 21, 2025. It is a firm fixed-price contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is not set-aside, has a ceiling value of $25,666.60 and a completion date of June 18, 2025. The contract provides for the delivery of RINVOQ ER 15 MG TABLET, a pharmaceutical product. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RINVOQ ER 30 MG TABLET, a prescription medication, with a ceiling value of $4,690.68 and a period of performance through May 16, 2025. The contract is a firm fixed-price type and is not set aside for any specific business category. Amerisourcebergen Drug Corp holds a significant...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB25FDQ65
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RINVOQ ER 30 MG TABLET. The contract has a ceiling value of $22,446.03 and an ultimate completion date of October 7, 2024. It is a firm fixed-price contract, with no set-aside designation. Amerisourcebergen holds several Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies, valued up to $999,999,999 and $750,000 respectively, which serve as primary vehicles for providing a wide range of pharmaceutical and medical supplies to support military treatment programs, veterans' healthcare, and other federal beneficiaries.

Generated 1/3/25, 9:06 AM